在全球 塑料污染治理 与 碳中和目标 的双重背景下， 上海蓝晶微生物科技有限公司 研发团队近期联合复旦 大学，在国际学术期刊 Metabolic Engineering 同期发表两项技术创新成果，并联合牛津大学在 Resources, Conservation & Recycling 发布全球首个基于真实生产数据的 聚羟基脂肪酸酯 （ PHA） 全生命周期碳足迹 研究。 这一系列工作通过自主开发的「 生物混动 」Biohybrid 技术体系， 在 PHA 工业化生产的单位产量、单位成 本控制和碳足迹控制方面达到文献报道最高水平。 油基碳源路线的理论突破与工业化验证 传统 PHA 生产依赖葡萄糖等糖类碳源，其理论质量转化率上限为 57%，对应碳源成本下限为 825 美元/吨。 蓝晶研发团队通过原子经济性分析发现，以长链脂肪酸为主的油脂碳源因其 75% 的碳原子占比且代谢无碳 损失，理论质量转化率可达 130%，碳源成本下限降低至 590 美元/吨。基于此，研究团队选择具有油脂代谢 优势的 罗氏真养菌 （ Cupriavidus necator H16） 为工业菌株，在补料分批发酵中实现 175 克/升的 PHA ...

Core Viewpoint - The article discusses the potential of synthetic biology to transform Mars into a habitable environment for humans, leveraging advanced technologies to engineer biological systems that can survive and thrive in Martian conditions [1][3]. Group 1: Synthetic Biology Overview - Synthetic biology is an emerging interdisciplinary field that integrates biology, physics, and chemistry to create new biological systems or products [2]. - Key technologies supporting synthetic biology include gene editing and sequencing, with CRISPR/Cas9 being a notable advancement that enhances precision and efficiency in genetic modifications [2]. - The potential economic value of synthetic biology is projected to reach $4 trillion within the next 10-20 years, with 60% of global products potentially being produced or repurposed using synthetic biology techniques [3]. Group 2: Mars Transformation Strategies - Microorganisms could be engineered to absorb harmful radiation on Mars, similar to extremophiles on Earth that thrive in harsh environments [4]. - Certain anaerobic microorganisms can detoxify Martian soil, which contains harmful perchlorates, by converting them into harmless chloride ions [4]. - There is a theoretical possibility of designing microorganisms that can survive on Mars and release oxygen and nitrogen, thereby altering the Martian atmosphere [5]. Group 3: Climate and Environmental Modifications - The average temperature on Mars is approximately -27°C, and one proposed method to warm the planet involves installing reflective mirrors in space to melt ice, although this could take around 200 years [6]. - Synthetic biology could expedite the warming process by engineering microorganisms to produce greenhouse gases, enhancing the greenhouse effect on Mars [6]. Group 4: Challenges and Considerations - The implementation of microbial engineering on Mars faces significant challenges, including the effects of low gravity and space radiation on biological processes [7]. - There are concerns about the ecological impact of introducing engineered microorganisms to Mars, which could disrupt any existing Martian life forms [7]. - Open discussions regarding the potential ecological consequences and guidelines for introducing synthetic biology to Mars are deemed essential for future missions [7].

【SynBioCon】 获 悉，5月10日，凯幸生物在长三角合成生物产业创新园举行投产仪式，高端生物活性分子专业化生产线正式投产。 凯幸生物成立于2024年5月，是 北京绿色康成生物技术有限公司 的子公司，是 清华大学 团队在生物技术领域数十年科研积淀转化形成的创新型企 业。 公司以新一代生物技术为核心，打造智能制造平台，实现了高端化学品的绿色制造，为全球市场提供可持续、高端生物活性原料解决方案。 德国国家工程院院士曾安平 、 清华大学教授刘德华 参加了投产仪式，并从产学研合作与技术转化角度，分享了对合成生物产业的洞察，肯定了凯幸生 物在合成生物领域的创新潜力，高度评价凯幸生物以技术突破带动产业升级，期待凯幸生物成为行业标 杆。 /D T 生物制造产业 交流 群/ 让专业的人聚在一起：绿色化工/生物基/食品和农业/美丽健康等10000+产业同行❤️↓ 此次发布的 "原料 + 标准" 组合，以 "中国原料" 叩响全球生物制造产业新篇，为合成生物领域国产化替代与标准体系建设注入强劲动能。同时，凯幸 生物还将进一步加强产业链合作，推动绿色、可持续的生物制造技术创新，持续为全球客户提供高品质、环保、高效的生物活性原料 ...

Group 1 - A new study published in the journal "Cell" highlights the use of generative artificial intelligence (AI) to design synthetic DNA sequences that act as "gene switches" to control gene expression in specific mammalian cells, marking a milestone in synthetic biology [1][2] - The AI model was trained to predict suitable combinations of DNA letters (A, T, C, G) to create DNA fragments that do not exist in nature, allowing for tailored gene expression patterns in specific cell types, such as enabling stem cells to develop into red blood cells instead of platelets [1][2] - The research team conducted over 64,000 experiments over five years to build the largest synthetic enhancer database for blood cells, testing 38 different transcription factor binding site arrangements and tracking enhancer activity across seven stages of blood cell development [2] Group 2 - The ability to create artificial enhancers that function as precise "on/off" switches in specific cells significantly reduces side effects on healthy cells, which is crucial for the development of next-generation gene therapies [2] - The study revealed interesting phenomena, such as some enhancer combinations exhibiting "negative synergistic effects," where two factors that individually promote gene expression can inhibit activity when combined, providing new insights into gene regulation [2][3] - This advancement opens new avenues for personalized medicine and precision gene therapy in the future [3]

点击 最 下方 "在看"和" "并分享，"关注"材料汇 添加 小编微信 ，遇见 志同道合 的你 正文 合成生物学:多学科的融合产物,生命科学的拆解和再创造的过程, 图:产业中的合成生物学主要指利用生物质发酵产生各种有价产品 图:DBTL循环是合成生物学的核心 刘虎虎, 田云, 走进合成生朝学 [J], 科学, 2023, 75 (02) : 30–34–69. 。 国信证券经济研究[ 适多必阅读正文之后的免费声明及其暗下所右内容 合成生物学:是生物基材料来源的方式之一,对生命编程的过程 图:人工基因组的设计、合成与应用 组装、重组与替换 图码千打展 人 TDNA 人工基因组 资料来源:CNKI,国信证券经济研究所整理 请务必阅读正文之后的免责声明及其硕下所有内容 ◆ 合成生物学是一门融合了生物学、信息学、基因组学、化学等多学科的交叉学科，在学习自然生命系统的基础上，建立人工生物，制造出满足人类需 求产品。合成生物学由于实现了从"认识生命"到"设计生命"的跨越,被学界誉为第三次生物技术革命。合成生物学的核心在于经改造的底盘细胞 通过其自身代谢，表达植入的特定基因从而获得目标产品，因此选择合适的底盘细胞并通过基因 ...

证券代码： 002019 证券简称：亿帆医药 亿帆医药股份有限公司投资者关系活动记录表 编号：2025001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2025 年 5 月 8 日（周四）下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用 | | | 网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总裁程先锋 | | 员姓名 | 2、董事、副总裁、董秘冯德崎 | | | 3、财务总监张大巍 | | | 4、董事兼副总裁林行 | | | 5、副总裁耿雨红 | | | 6、独立董事曾玉红 | | 投资者关系活动 | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、想问程总。上次交流会程总说市值 ...

Group 1: Financial Performance - The company's net profit for 2024 is expected to decline due to four main factors: increased fixed asset depreciation, a 37% year-on-year increase in sales team size leading to higher sales expenses, increased R&D investment, and a structural decline in gross margin of core products due to intensified market competition [2][3] - In Q1 2025, the company reported a net profit growth of approximately 360%, attributed to investment income of about 40 million yuan and the efficient operation of the Thai production base [3] Group 2: Operational Insights - The Thai factory achieved approximately 90 million yuan in revenue and 19 million yuan in net profit in Q1 2025, primarily producing vanillin and cooling agents [3] - Long-term contracts account for about 80% of the company's total revenue, with pricing strategies adjusted based on market supply and demand dynamics [3][4] Group 3: Expansion and Product Development - The first phase of the Thai base is fully operational, with the second phase expected to be completed around August 2025, and the third phase in preliminary planning [3] - The company is actively exploring new product developments, such as ambroxan, to meet diverse market and consumer demands [4] - Strategic investment in ABT shares aims to strengthen sales channels and enhance market competitiveness [4]

证券代码： 300430 证券简称：诚益通 北京诚益通控制技术集团股份有限公司 投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | | 新闻发布会 路演活动 □ □ | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 5 月 日 (周四) 下午 15:00~17:00 | 8 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长梁凯 | | | 员姓名 | 2、董事、副总经理、财务总监卢振华 | | | | 3、董事会秘书张金婷 | | | | 4、独立董事王福清 | | | | 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | 1、【查询-00 ...

Core Insights - The company aims to enhance its market competitiveness in the food, nutrition, and beauty sectors by investing in Peisheng Biotechnology to promote the application of new raw materials in consumer products [1][2] - The establishment of Beijing Kaiyuan Juliy aims to leverage the capital and talent resources in the capital city to improve the company's professional capabilities in business expansion and capital operations, driving a dual strategy of "industry + capital" [1] Product Pricing and Market Strategy - The sales prices of products such as erythritol, blended sugars, and allulose will fluctuate based on specifications, business conditions, and market competition, with a dynamic adjustment throughout the year [1] - The company has a competitive edge in production technology and cost control for tagatose, which is currently in an active promotion phase, with market pricing being continuously optimized based on market feedback [1] New Product Development - The company is committed to innovation-driven growth, focusing on synthetic biology and advancing new product research and industrialization [2] - A new 10,000-ton production line for allulose is under rapid construction, aiming to secure a first-mover advantage in the fast-growing market once approved for domestic use [2] - The existing 85,000-ton erythritol production line is undergoing upgrades to enable flexible manufacturing capabilities across multiple products, significantly reducing new product line construction costs and enhancing market responsiveness [2] - The company is optimizing production processes for high-activity biological raw materials like glycerol glycosides and sweet tea glycosides, with plans for small-scale production based on technology maturity and market demand [2]

Core Viewpoint - The petrochemical industry is undergoing significant transformation, with a focus on technology-driven quality and efficiency improvements in new capacity additions, highlighting opportunities in high-end and differentiated markets such as new materials and fine chemicals [1] Group 1: Role of Engineering Construction Enterprises - Engineering construction enterprises should emphasize innovation leadership to seize new market opportunities and inject strong momentum into sustainable development [1] - The enterprises need to enhance their technological innovation capabilities and establish a comprehensive innovation system focused on results transformation [1] - There is a need to explore core technologies related to energy transition and prioritize research on high-performance polymer materials and biomanufacturing as part of a "second growth curve" [1] Group 2: Innovation Platforms and Digital Development - Engineering construction enterprises should establish platforms for technology policy research, pilot verification, and technology application to facilitate the industrialization of technological achievements [2] - Collaboration with universities, research institutions, and enterprises is essential to integrate various technological verification resources and promote technology sourcing and transformation [2] - The enterprises must advance digital and intelligent development, enhancing information management and integrating artificial intelligence into business processes to create exemplary models in the engineering construction sector [2]